Biomarin Pharmaceutical (BMRN) Other Non-Current Liabilities: 2009-2025
Historic Other Non-Current Liabilities for Biomarin Pharmaceutical (BMRN) over the last 17 years, with Sep 2025 value amounting to $163.1 million.
- Biomarin Pharmaceutical's Other Non-Current Liabilities rose 27.87% to $163.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $163.1 million, marking a year-over-year increase of 27.87%. This contributed to the annual value of $128.8 million for FY2024, which is 7.41% up from last year.
- According to the latest figures from Q3 2025, Biomarin Pharmaceutical's Other Non-Current Liabilities is $163.1 million, which was up 9.57% from $148.8 million recorded in Q2 2025.
- In the past 5 years, Biomarin Pharmaceutical's Other Non-Current Liabilities registered a high of $163.1 million during Q3 2025, and its lowest value of $92.4 million during Q1 2023.
- Moreover, its 3-year median value for Other Non-Current Liabilities was $119.9 million (2023), whereas its average is $122.8 million.
- Per our database at Business Quant, Biomarin Pharmaceutical's Other Non-Current Liabilities declined by 17.87% in 2021 and then grew by 27.87% in 2025.
- Biomarin Pharmaceutical's Other Non-Current Liabilities (Quarterly) stood at $98.4 million in 2021, then rose by 1.68% to $100.0 million in 2022, then increased by 19.92% to $119.9 million in 2023, then grew by 7.41% to $128.8 million in 2024, then climbed by 27.87% to $163.1 million in 2025.
- Its last three reported values are $163.1 million in Q3 2025, $148.8 million for Q2 2025, and $129.7 million during Q1 2025.